Study to Evaluate the Effects of MBX-8025 in Patients With HoFH

Phase 2 Completed 13 enrolled Gilead Sciences

NaSingle-groupOpen-labelTreatment

Summary

A 12-week, open-label, dose-escalating, phase 2 study to evaluate the effects of MBX-8025 in patients with Homozygous Familial Hypercholesterolemia (HoFH).

Timeline

Start: 2015-04
Primary completion: 2016-02
Completion: 2016-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Seladelpar	Small molecule	200 mg	—

Study to Evaluate the Effects of MBX-8025 in Patients With HoFH

Summary

Timeline

Drugs

Indications